Congo vs Madagascar: Share of the population living with HIV receiving antiretroviral therapy
Congo
33.7%
in 2024
Madagascar
29.3%
in 2024
Congo rank
141st
Madagascar rank
142nd
Share of the population living with HIV receiving antiretroviral therapy over time
- Congo
- Madagascar
How they compare
Congo currently reports 33.7% against 29.3% in Madagascar, a difference of 4.4%.
That makes Congo's figure about 1.2 times Madagascar's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Madagascar ahead.
Congo ranks 141st and Madagascar ranks 142nd of 149 countries.
Congo has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Congo | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 3.7% | 0.4% | 3.3% | Congo |
| 2010s | 19.8% | 3.7% | 16.1% | Congo |
| 2020s | 28.0% | 18.9% | 9.1% | Congo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Congo or Madagascar?
- Congo, at 33.7% against 29.3% in Madagascar as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Congo and Madagascar?
- 4.4%, with Congo ahead.
- How many years of comparable data are there for Congo and Madagascar?
- 35 years are reported by both, from 1990 to 2024.
- How do Congo and Madagascar rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Congo ranks 141st and Madagascar ranks 142nd of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.